PROGRAM
All Times are EST
Program is subject to change
Friday, February 10, 2023
| 7:50 am | Welcome and Overview / Pre-Program Test Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD |
| Session I: Non-Exudative AMD Moderators: Philip J. Rosenfeld, MD, PhD, Giovanni Gregori, PhD, and Zohar Yehoshua, MD, MHA Panelists: Gregory S. Hageman, PhD, Giovanni Staurenghi, MD, FARVO, FEBO, Christine A. Curcio, FARVO, Lawrence Singerman, MD, Aaron Y. Lee, MD, MSCI, R. Theodore Smith, MD, Mengxi Shen, MD, Justis P. Ehlers, MD, and Baruch D. Kuppermann, MD, PhD |
|
| 8:00 | Age-Related Macular Degeneration: A Tale of Two Biologies Gregory S. Hageman PhD |
| 8:10 | High Resolution OCT of AMD Giovanni Staurenghi, MD, FARVO, FEBO |
| 8:20 | Imaging and Plasma Measures of Xanthophyll Carotenoids in Early Stages of AMD: Elucidating Lutein and Zeaxanthin Bioavailability in the ALSTAR2 Baseline Cohort Christine A. Curcio, PhD, FARVO |
| 8:30 | Short Form of the National Eye Institute Visual Function Questionnaire-25 {NEI VFQ-25}: The VFQ-7 Lawrence Singerman, MD |
| 8:40 | Deep Learning Techniques for AMD Biomarkers Aaron Y. Lee, MD, MSCI |
| 8:50 | Subretinal Drusenoid Deposits are Markers for Co-existent High-risk Vascular Diseases R. Theodore Smith, MD |
| 9:00 | Correlations Between Central CC Flow Impairment and Cone Visual Acuity Measurements Mengxi Shen, MD |
| 9:10 | Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint Justis P. Ehlers, MD |
| 9:20 | Reversing Vision Loss in Dry AMD: Matching Mechanism with the Right Patient Population and Stage of Disease Baruch D. Kuppermann, MD, PhD |
| Session II: Predicting Disease Progression in Non-Exudative AMD Moderators: Jaclyn L. Kovach, MD, Sander R. Dubovy, MD, and Philip J. Rosenfeld, MD, PhD Panelists: Frank G. Holz, FEBO, FARVO, David Sarraf, MD, Ruikang Wang, PhD, Philip J. Rosenfeld, MD, PhD, Pearse A. Keane, MD, MSc, FRCOphth MRCSI, Emily Y. Chew, MD, and Gemmy Cheung MBBS, FRCOphth, FAMS, MCI |
|
| 9:30 | MACUSTAR Study in Intermediate AMD: Novel Findings Frank G. Holz, FEBO, FARVO |
| 9:40 | Progression of iRORA to cRORA: Challenges in Implementation into Clinical Trials of AMD David Sarraf, MD |
| 9:50 | Automated Algorithms to Quantify Geographic Atrophy and Pigment Burden in AMD Ruikang Wang, PhD |
| 10:00 | The Onset and Progression of Persistent Hypertransmission Defects: A Novel Clinical Trial Endpoint for Studying iAMD Philip J. Rosenfeld, MD, PhD |
| 10:10 | Deep learning in Geographic Atrophy - the Impending Need for AI-enabled Therapeutics Pearse A. Keane, MD, MSc, FROphth, MRCSI |
| 10:20 | The Update of AREDS/AREDS2 on GA Progression and the Role of Reticular Pseudodrusen in AMD Progression Emily Y. Chew, MD |
| 10:30 | Macular Atrophy Phenotypes and Progression Rates in Asians Compared to Non-Asians Gemmy Cheung MBBS, FRCOphth, FAMS, MCI |
| Session III: Therapies for Non-Exudative AMD Moderators: Ninel Z. Gregori, MD, Philip J. Rosenfeld, MD, PhD, and Raquel Goldhardt, MD, FACS Panelists: Pedro Lylyk, MD, Amir H. Kashani, MD, PhD, Arshad M. Khanani, MD, MA, David Eichenbaum, MD, David R. Lally, MD, FASRS, Glenn J. Jaffe, MD, and Peter K. Kaiser, MD |
|
| 10:40 | Intracranial Ophthalmic Angioplasty (IOA): Safety and Preliminary Results, a Better Way to Improve Retinal and Choroidal Perfusion Pedro Lylyk, MD |
| 10:50 | Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy (GA) due to Age-Related Macular Degeneration Jeffrey S. Heier, MD |
| 11:00 | Preliminary Results of a Phase 1/2a Study Using Induced Pluripotent Stem Cell Derived Retinal Pigment Epithelium for Treatment of Advanced Dry Age Related Macular Degeneration with Geographic Atrophy Amir H. Kashani, MD, PhD |
| 11:10 | Results from the Phase II CATALINA Study Evaluating NGM621 for the Treatment of Geographic Atrophy Arshad M. Khanani, MD, MA |
| 11:20 | GATHER1/GATHER2: Comparison of Trial Design and Baseline Patient Populations Influencing Lesion Growth David Eichenbaum, MD |
| 11:30 | C5 Inhibition with Avacincaptad Pegol for the Treatment of Geographic Atrophy: Efficacy Results from the Phase 3 GATHER2 Trial David R. Lally, MD, FASRS |
| 11:40 | Foveal Invasion in GATHER2 Glenn J. Jaffe, MD |
| 11:50 | Safety of the Phase 2/3 Gather1 and Gather2 Studies Peter K. Kaiser, MD |
| Session IV: Pegcetacoplan Results for the Treatment of GA: Derby and Oaks Trials Moderators: Jorge Fortun, MD, Jayanth Sridhar, MD, and Philip J. Rosenfeld, MD, PhD Panelists: Eleonora M. Lad, MD, PhD, Rishi Singh, MD, Jeffrey S. Heier, MD, and Nadia K. Waheed, MD, MPH |
|
| 12:00 pm | 2-year Outcomes of the Pegcetacoplan Phase 3 Derby and Oaks Clinical Trials for GA: Baseline Characteristics and Efficacy Eleonora M. Lad, MD, PhD |
| 12:10 | 2-year Outcomes of the Pegcetacoplan Phase 3 Derby and Oaks Clinical Trials for GA: Safety and Exudative Changes Rishi Singh, MD |
| 12:20 | Analytical Strategies for Microperimetry in GA trials: The Oaks Trial Experience Nadia K. Waheed, MD, MPH |
| 12:30 | A Deeper Dive into the 24-Month Results of Derby and Oaks Trials Jeffrey S. Heier, MD |
| 12:40 | Panel Discussion: Derby and Oaks Trials |
| 12:50 | Session V Panel Discussion on Translating the Results of Clinical Trials to the Real-World Treatment of Late Nonexudative AMD Moderators: Philip J. Rosenfeld MD, PhD Panelists: SriniVas R. Sadda, MD, Frank G. Holz, FEBO, FARVO, Emily Y. Chew, MD, Arshad M. Khanani, MD, MA, David Eichenbaum, MD, David R. Lally, MD, FASRS, Peter K. Kaiser, MD, Eleonora Lad, MD, PhD, Rishi Singh, MD, Jeffrey S. Heier, MD, Lawrence Singerman, MD, Giovanni Staurenghi, MD, and Nadia K. Waheed, MD, MPH |
| Session VI: Exudative AMD Moderators: Luis J. Haddock, MD, Maura Di Nicola, MD, and Thomas A. Albini, MD Panelists: Richard F. Spaide, MD, SriniVas R. Sadda, MD, K. Bailey Freund, MD, Jean-Francois Korobelnik MD, PhD, Omer Trivizki, MD, MBA, Ursula Schmidt-Erfurth, MD, Anat Loewenstein, MD, Daniel F. Martin, MD, Nancy Holekamp, MD, Usha Chakravarthy, MD, and Giuseppe Querques, MD |
|
| 1:20 | Inflammatory Cell Involvement in Neovascular Age-Related Macular Degeneration Richard F. Spaide, MD |
| 1:30 | OCT Risk Factors for Development of Macular Neovascularization SriniVas R. Sadda, MD |
| 1:40 | Deep Learning for Automatic Prediction of Early Activation of Treatment-naive Quiescent MNV Giuseppe Querques, MD |
| 1:50 | Deep Retinal Age-Related Microvascular Anomalies (DRAMA): A Mimic or Precursor of Intraretinal Neovascularization? K. Bailey Freund, MD |
| 2:00 | Exudation Assessment on SD-OCT in Wet AMD: B-Scan or Mapping? Jean-Francois Korobelnik MD, PhD |
| 2:10 | Remote Monitoring of Exudative AMD Patients using Macular Thickness Measurements and Optimal Change Thresholding Omer Trivizki, MD, MBA |
| 2:20 | Automated Quantification of Retinal Fluid in Real-World Disease Management Ursula Schmidt-Erfurth, MD |
| 2:30 | AI-Derived Fluid Dynamics in Exudative Retinal Diseases Anat Loewenstein, MD |
| 2:40 | Home OCT and its Potential Role in the Management of Neovascular AMD Daniel F. Martin, MD |
| 2:50 | Home OCT Guided Anti-VEGF Therapy in Patients with nAMD – First Longitudinal Study Results Nancy Holekamp, MD |
| 3:00 | Does Atrophy Precede or Follow Outer Retinal Fibrosis in Treated Neovascular AMD Usha Chakravarthy, MD |
| 3:10 | Adjourn until Saturday, Feb. 11th at 8:00 am |
Saturday, February 11, 2023
| 7:50 am | Welcome and Overview Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD |
| Session VII: Emerging and Current Therapies for Exudative AMD Moderators: Janet L. Davis, MD, Thomas A. Albini, MD, and Nicolas A. Yannuzzi, MD Panelists: Tong Li, MD, PhD, Andrew A. Moshfeghi, MD, MBA, Xiaodong Sun, MD, PhD, Charles C. Wykoff, MD, PhD, Justis P. Ehlers, MD, Allen C. Ho, MD, Mark R. Barakat, MD, David M. Brown, MD, FACS, Carl D. Regillo, MD, Robyn Guymer, MBBS, PhD, and Seung-Young Yu, MD |
|
| 8:00 | Update on a Hydrogel-Based Intravitreal Axitinib Intravitreal Implant (OTX-TKI) for the Treatment of Neovascular AMD Andrew A. Moshfeghi, MD, MBA |
| 8:10 | Primary Endpoint Results of a Phase II study of Efdamrofusp Alfa: A Bispecific Fusion Protein Targeting VEGF and Complement in Patients with nAMD: Multicentre, Randomized,Active Controlled Trial
Xiaodong Sun, MD, PhD |
| 8:20 | LX102 Gene Therapy for Neovascular AMD Tong Li, MD, PhD |
| 8:30 | Intravitreal ADVM-022 Gene Therapy for Wet AMD: Overview of 2-Year Results with Detailed Analysis of Fluid Volatility and Outer Retinal Integrity Justis P. Ehlers, MD |
| 8:40 | An Update on Subretinal RGX-314 Gene Therapy in nAMD Charles C. Wykoff, MD, PhD |
| 8:50 | Long-Term Follow-Up of Durable Subretinal RGX-314 Gene Therapy for Exudative AMD Allen C. Ho, MD |
| 9:00 | Suprachoroidal Therapy for Neovascular AMD Mark R. Barakat, MD |
| 9:10 | Efficacy and Safety of High-Dose (8.0 mg) Aflibercept of Treatment for Wet AMD: 48-Week Results from PULSAR David M. Brown, MD, FACS |
| 9:20 | Talon Phase 3b Study Results: Brolucizumab vs. Aflibercept in a Matched Treat-and-Extend Superiority Study for Neovascular AMD Carl D. Regillo, MD |
| 9:30 | VOYAGER: An Innovative, Global, Observational Study to Gain Real-World Insights into the Long-term Utilisation of Faricimab and the Port Delivery System with Ranibizumab for the Treatment of nAMD and DME Robyn Guymer, MBBS, PhD |
| 9:40 | Three-Year Clinical Outcomes of Polypoidal Choroidal Vasculopathy Based on Swept-Source OCT Angiography Seung-Young Yu, MD |
| Session VIII: Diabetic Retinopathy-Imaging and Treatment Moderators: Justin H. Townsend, MD, Harry W. Flynn, Jr., MD, and Basil Williams, MD Panelists: James G. Fujimoto, PhD, Toshinori Murata, MD, PhD, Peter K. Kaiser, MD, Peter A. Campochiaro, MD, Robert Bhisitkul, MD, PhD, Arshad M. Khanani, MD, MA, Dante Pieramici, MD, David S. Boyer, MD, Jennifer Sun MD, and Jayanth Sridhar, MD |
|
| 9:50 | OCT Angiography in Diabetic Retinopathy Harry W. Flynn, Jr., MD |
| 10:00 | Advances in Ultrahigh Speed SS-OCT Angiography for Assessing Retinal Blood Flow James G. Fujimoto, PhD |
| 10:10 | The Balance Between Leakage and Drainage in Macular Edema Toshinori Murata, MD, PhD |
| 10:20 | Efficacy and Safety Data for APX3330, a Novel Oral Drug Candidate for DR/DME from the ZETA-1 Phase 2b Trial Peter K. Kaiser, MD |
| 10:30 | Results of the Phase 2 BEHOLD Trial of UBX1325, A Novel Senolytic Agent for Diabetic Macular Edema Robert Bhisitkul, MD, PhD |
| 10:40 | Suprachoroidal Therapy for Diabetic Retinopathy Peter A. Campochiaro, MD |
| 10:50 | Port Delivery System with Ranibizumab (PDS) in Patients With Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial Arshad M. Khanani, MD, MA |
| 11:00 | Port Delivery System with Ranibizumab (PDS) in Patients With Diabetic Retinopathy: Primary Analysis Results of the Phase 3 Pavilion Trial Dante Pieramici, MD |
| 11:10 | Efficacy and Safety of High-dose (8 mg) Aflibercept for Treatment of DME: 48-Week Results from PHOTON David S. Boyer, MD |
| 11:20 | Results of DRCR Retina Network Protocol AC Jennifer Sun, MD |
| 11:30 | Changes in Prescribing Trends of Intravitreal Anti-Vascular Endothelial Growth Factor Antagonists with Initial Publication of DRCR.net Jayanth Sridhar, MD |
| Session IX: Faricimab in Retinal Vacular Diseases Moderators: Harry W. Flynn, Jr., MD, Philip J. Rosenfeld, MD, PhD, and William E. Smiddy, MD Panelists: Karl G. Csaky, MD, PhD, Caroline Baumal, MD, Ramin Tadayoni, MD, PhD, Peter A. Campochiaro, MD, Robert Bhisitkul, MD, PhD, Arshad M. Khanani, MD, MA, Dante Pieramici, MD, David S. Boyer, MD, Jennifer Sun, MD, Jayanth Sridhar, MD, and Justin H. Townsend, MD |
|
| 11:40 | Ang2/VEGF Biology and Intraocular Suppression Following Intravitreal Administration of Faricimab Karl G. Csaky, MD, PhD |
| 11:50 | Faricimab in RVO - Results from the BALATON and COMINO Phase 3 Studies Ramin Tadayoni, MD, PhD |
| 12:00 pm | Faricimab in nAMD and DME - Latest Updates Caroline Baumal, MD |
| 12:10 | Panel Discussion: Faricimab in Retinal Vascular Diseases |
| Session X: Retinal Vascular Diseases and Uveitis Moderators: Thomas A. Albini MD, Stephen G. Schwartz, MD, MBA, and Zelia Maria Correa, MD, PhD Panelists: Darius M. Moshfeghi, MD, Michael S. Ip, MD, Diana V. Do, MD, Martin Friedlander, MD, PhD, Thomas A. Albini, MD, Lawrence A. Yannuzzi, MD, Steven Yeh, MD, and Sunil K. Srivastava, MD |
|
| 12:20 | Avascular Retina as the Risk Factor for Failure in BEAT ROP and anti-VEGF Clinical Trials Darius M. Moshfeghi, MD |
| 12:30 | Efficacy and Safety of Intravitreal Aflibercept versus Laser Photocoagulation for ROP: Results from the Phase 3 BUTTERFLEYE Trial Darius M. Moshfeghi, MD |
| 12:40 | Treatment Outcomes with Anti-VEGF Therapy for CRVO and BRVO: An Analysis of the Vestrum Database Michael S. Ip, MD |
| 12:50 | Update on KSI-301 and the BEACON Phase III Pivotal Study for Retinal Vein Occlusion Diana V. Do, MD |
| 1:00 | Results of the Phase 3 MacTel2 CNTF Trial Martin Friedlander, MD, PhD |
| 1:10 | Diagnostic Testing in Uveitis Thomas A. Albini, MD |
| 1:20 | Acute Zonal Occul Outer Retinopathy (AZOOR): Relentless Progression Lawrence A. Yannuzzi, MD |
| 1:30 | Integrated Analysis of Phase 3 Clinical Trials on Suprachoroidal Triamcinolone Acetonide for Macular Edema Due to Noninfectious Uveitis: From Evidence to Clinical Practice Steven Yeh, MD |
| 1:40 | Inflammatory Complications of Gene Therapy Sunil K. Srivastava, MD |
| Session XI: Inherited Retinal Degenerations Moderators: Philip J. Rosenfeld MD PhD, Byron L. Lam MD, and Harry W. Flynn, Jr., MD Panelists: Carel B. Hoyng, MD, Quan Dong Nguyen, MD, MSc, and Byron L. Lam, MD |
|
| 1:50 | Stargardt Disease, Phenotyping, and Towards Clinical Trials Carel B. Hoyng, MD |
| 2:00 | Tinlarebant (LBS-008) for Stargardt Disease: The Story Continues Quan Dong Nguyen, MD, MSc |
| 2:10 | Treatments and Clinical Trials for Inherited Retinal Disease Byron L. Lam, MD |
| 2:20 | Post-Program Test and Closing Remarks |